Health Care & Life Sciences » Biotechnology | ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. | Cash Flow

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,230.90
2,141.40
2,121.00
3,455.00
6,020.00
10,167.10
Depreciation, Depletion & Amortization
50.30
8.90
7.60
6.70
6.70
6.70
Other Funds
-
-
43.50
-
-
1,074.90
Funds from Operations
2,108.60
1,453.30
1,564.40
2,874.10
5,327.60
9,085.50
Changes in Working Capital
103.30
84.60
9.00
330.30
371.80
441.70
Net Operating Cash Flow
2,005.20
1,368.70
1,573.40
2,543.80
5,699.40
8,643.70
Capital Expenditures
1.30
2.00
-
-
-
Purchase/Sale of Investments
92.70
-
41.00
0.20
0.20
Net Investing Cash Flow
91.40
2.00
41.00
0.20
0.20
Issuance/Reduction of Debt, Net
-
-
87.20
-
112.30
Net Financing Cash Flow
1,134.50
1,258.90
2,492.60
2,352.80
6,677.30
Net Change in Cash
779.30
111.80
878.20
191.20
977.70
Free Cash Flow
2,006.50
1,370.70
1,573.40
-
5,699.40
Change in Capital Stock
1,134.50
1,258.90
2,361.90
2,352.80
6,789.60

About ProMIS Neurosciences

View Profile
Address
1920 Yonge Street
Toronto Ontario M4S 3E2
Canada
Employees -
Website http://www.promisneurosciences.com
Updated 07/08/2019
ProMIS Neurosciences, Inc. operates as a development stage biotech company. It discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.